Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2024
First quarter (January-March 2024) · Operating profit/loss amounted to SEK - 5,433,422 (-2,265,857). · Loss for the period amounted to SEK - 5,369,677 (-2,266,329). · Cash flow from operating activities totaled SEK -9,264,396 (-2,035,828). · Earnings per share before dilution totaled SEK – 0.26 (-0,11) ). Earnings per share after dilution totaled SEK -0.26 (-0.11). Key events during the first quarter · Elicera participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand.